Screener
AnaptysBio, Inc. ANAB Advance Future Royalties Liability Noncurrent
Advance Future Royalties Liability Noncurrent at other companies
Other financials
Where this comes from
Reported directly by AnaptysBio, Inc. in its filing.
Tagged under the XBRL concept anab:AdvanceFutureRoyaltiesLiabilityNoncurrent.
The source filing: AnaptysBio, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:20 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219515
| Line item | March 31, 2026(unaudited) | December 31, 2025 |
|---|---|---|
| Accrued expenses | 32,065 | 32,674 |
| Current portion of operating lease liability | 2,120 | 2,080 |
| Total current liabilities | 41,702 | 38,625 |
| Liability related to sale of future royalties | 263,742 | 276,528 |
| Operating lease liability, net of current portion | 11,493 | 12,032 |
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at March 31, 2026 and December 31, 2025, respectively | — | — |
| Common stock, $0.001 par value, 500,000 shares authorized, 29,031 shares and 28,019 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 29 | 28 |
Item 1. Consolidated Financial Statements
FAQ
- What is AnaptysBio, Inc.'s advance future royalties liability noncurrent?
- AnaptysBio, Inc. (ANAB) reported advance future royalties liability noncurrent of $263.74M in Q1 2026.
- How has AnaptysBio, Inc.'s advance future royalties liability noncurrent changed year-over-year?
- AnaptysBio, Inc.'s advance future royalties liability noncurrent decreased by 20.2% year-over-year, from $330.38M to $263.74M.
- What does advance future royalties liability noncurrent mean?
- This metric represents the long-term portion of obligations arising from upfront payments or financing arrangements received in exchange for future royalty streams on product sales. It reflects the company's commitment to share future revenue with third-party investors or partners beyond the next twelve months. Tracking this liability is essential for assessing the company's long-term revenue retention and the impact of past financing activities on future cash flows.
Ask your AI about AnaptysBio, Inc.'s advance future royalties liability noncurrent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude